Approval of Un-Audited Financial Results of the Company for the Quarter ended June 30, 2025 along with the Limited Review Report thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories reported a net loss of Rs. 118.05 lakh (approx Rs. 1.18 crore) for Q1 FY26 (quarter ended June 30, 2025), against a loss of Rs. 33.96 lakh in the year-ago quarter. Revenue from operations was nil, with total income of just Rs. 2.07 lakh. The loss was driven by a massive spike in administrative and other expenses to Rs. 1,180.12 lakh, up from Rs. 1.29 lakh in Q1 FY25. The board also approved a change of company name, a shift of the registered office from Kalyan (Maharashtra) to Ahmedabad (Gujarat), and an amendment to the main object clause to venture into wholesale and commodity trading. The 83rd AGM is scheduled for September 24, 2025, with book closure from September 17 to September 24.
The near-zero revenue combined with a 900x jump in administrative expenses is a serious red flag for shareholders, suggesting the core pharma business is non-operational. The pivot to commodity trading and the move to Gujarat signal a possible restructuring, but execution risk is high. Expect negative stock reaction and increased scrutiny on going-concern status.